EMILIO
ESTEBAN GONZALEZ
Profesor Titular de Universidad
Hospital Vall d'Hebron
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (20)
2024
-
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non–small cell lung cancer: KEYNOTE-782
Lung Cancer, Vol. 190
-
Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer
Cancer Epidemiology Biomarkers and Prevention, Vol. 33, Núm. 3, pp. 419-425
2023
-
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study
Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 1992-1998
2021
-
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
Annals of Oncology, Vol. 32, Núm. 7, pp. 881-895
2020
-
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 3, pp. 387-397
-
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 14, pp. 1505-1517
2018
-
Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer
New England Journal of Medicine, Vol. 378, Núm. 22, pp. 2078-2092
-
Radium-223 international early access program: Results from the Spanish subset
Future Oncology, Vol. 14, Núm. 1, pp. 41-50
2017
-
Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Scientific Reports, Vol. 7
-
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421
-
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment
Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190
2016
-
Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations
Targeted Oncology, Vol. 11, Núm. 2, pp. 129-141
-
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study
BMC Cancer, Vol. 16, Núm. 1
2014
2013
-
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130
-
Dolor como factor predictor de depresión en el paciente oncológico: estudio de casos y controles. Estudio D-PRESS
Revista de la Sociedad Espanola del Dolor, Vol. 20, Núm. 3, pp. 113-121
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572
2012
-
Análisis económico de oxicodona LP/naloxona LP en el manejo del dolor intenso y el estrenimiento asociado al tratamiento con opioides en España
Pharmacoeconomics - Spanish Research Articles, Vol. 9, Núm. 1, pp. 21-32
-
Recommendations for the optimal management of early and advanced urothelial carcinoma
Cancer Treatment Reviews, Vol. 38, Núm. 5, pp. 431-441
2009
-
Recommendations from the Spanish oncology genitourinary group for the treatment of metastatic renal cancer
Cancer Chemotherapy and Pharmacology